BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 23933574)

  • 1. Endogenous alpha-synuclein influences the number of dopaminergic neurons in mouse substantia nigra.
    Garcia-Reitboeck P; Anichtchik O; Dalley JW; Ninkina N; Tofaris GK; Buchman VL; Spillantini MG
    Exp Neurol; 2013 Oct; 248():541-5. PubMed ID: 23933574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced complement of dopaminergic neurons in the substantia nigra pars compacta of mice with a constitutive "low footprint" genetic knockout of alpha-synuclein.
    Goloborshcheva VV; Chaprov KD; Teterina EV; Ovchinnikov R; Buchman VL
    Mol Brain; 2020 May; 13(1):75. PubMed ID: 32393371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra.
    St Martin JL; Klucken J; Outeiro TF; Nguyen P; Keller-McGandy C; Cantuti-Castelvetri I; Grammatopoulos TN; Standaert DG; Hyman BT; McLean PJ
    J Neurochem; 2007 Mar; 100(6):1449-57. PubMed ID: 17241127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nigral overexpression of alpha-synuclein in the absence of parkin enhances alpha-synuclein phosphorylation but does not modulate dopaminergic neurodegeneration.
    Van Rompuy AS; Oliveras-Salvá M; Van der Perren A; Corti O; Van den Haute C; Baekelandt V
    Mol Neurodegener; 2015 Jun; 10():23. PubMed ID: 26099628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model.
    Wegrzynowicz M; Bar-On D; Calo' L; Anichtchik O; Iovino M; Xia J; Ryazanov S; Leonov A; Giese A; Dalley JW; Griesinger C; Ashery U; Spillantini MG
    Acta Neuropathol; 2019 Oct; 138(4):575-595. PubMed ID: 31165254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration.
    Oliveras-Salvá M; Van der Perren A; Casadei N; Stroobants S; Nuber S; D'Hooge R; Van den Haute C; Baekelandt V
    Mol Neurodegener; 2013 Nov; 8():44. PubMed ID: 24267638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A dual role for α-synuclein in facilitation and depression of dopamine release from substantia nigra neurons in vivo.
    Somayaji M; Cataldi S; Choi SJ; Edwards RH; Mosharov EV; Sulzer D
    Proc Natl Acad Sci U S A; 2020 Dec; 117(51):32701-32710. PubMed ID: 33273122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine and α-synuclein dysfunction in Smad3 null mice.
    Tapia-González S; Giráldez-Pérez RM; Cuartero MI; Casarejos MJ; Mena MÁ; Wang XF; Sánchez-Capelo A
    Mol Neurodegener; 2011 Oct; 6():72. PubMed ID: 21995845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased expression of serum- and glucocorticoid-inducible kinase 1 (SGK1) promotes alpha-synuclein increase related with down-regulation of dopaminergic cell in the Substantia Nigra of chronic MPTP-induced Parkinsonism mice and in SH-SY5Y cells.
    Yeo S; Sung B; Hong YM; van den Noort M; Bosch P; Lee SH; Song J; Park SK; Lim S
    Gene; 2018 Jun; 661():189-195. PubMed ID: 29604467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aldehyde dehydrogenase 1 defines and protects a nigrostriatal dopaminergic neuron subpopulation.
    Liu G; Yu J; Ding J; Xie C; Sun L; Rudenko I; Zheng W; Sastry N; Luo J; Rudow G; Troncoso JC; Cai H
    J Clin Invest; 2014 Jul; 124(7):3032-46. PubMed ID: 24865427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alterations in the nigrostriatal system following conditional inactivation of α-synuclein in neurons of adult and aging mice.
    Ninkina N; Tarasova TV; Chaprov KD; Roman AY; Kukharsky MS; Kolik LG; Ovchinnikov R; Ustyugov AA; Durnev AD; Buchman VL
    Neurobiol Aging; 2020 Jul; 91():76-87. PubMed ID: 32224067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutant α-Synuclein Overexpression Induces Stressless Pacemaking in Vagal Motoneurons at Risk in Parkinson's Disease.
    Lasser-Katz E; Simchovitz A; Chiu WH; Oertel WH; Sharon R; Soreq H; Roeper J; Goldberg JA
    J Neurosci; 2017 Jan; 37(1):47-57. PubMed ID: 28053029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of MicroRNA-7 Regulation Leads to α-Synuclein Accumulation and Dopaminergic Neuronal Loss In Vivo.
    McMillan KJ; Murray TK; Bengoa-Vergniory N; Cordero-Llana O; Cooper J; Buckley A; Wade-Martins R; Uney JB; O'Neill MJ; Wong LF; Caldwell MA
    Mol Ther; 2017 Oct; 25(10):2404-2414. PubMed ID: 28927576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene co-expression analysis of the human substantia nigra identifies BMP2 as a neurotrophic factor that can promote neurite growth in cells overexpressing wild-type or A53T α-synuclein.
    Goulding SR; Sullivan AM; O'Keeffe GW; Collins LM
    Parkinsonism Relat Disord; 2019 Jul; 64():194-201. PubMed ID: 31000327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of truncated human alpha-synuclein (1-120) on dopaminergic cells in a transgenic mouse model of Parkinson's disease.
    Michell AW; Tofaris GK; Gossage H; Tyers P; Spillantini MG; Barker RA
    Cell Transplant; 2007; 16(5):461-74. PubMed ID: 17708336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PGC-1α activity in nigral dopamine neurons determines vulnerability to α-synuclein.
    Ciron C; Zheng L; Bobela W; Knott GW; Leone TC; Kelly DP; Schneider BL
    Acta Neuropathol Commun; 2015 Apr; 3():16. PubMed ID: 25853296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated alpha-synuclein mRNA levels in individual UV-laser-microdissected dopaminergic substantia nigra neurons in idiopathic Parkinson's disease.
    Gründemann J; Schlaudraff F; Haeckel O; Liss B
    Nucleic Acids Res; 2008 Apr; 36(7):e38. PubMed ID: 18332041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of autophagy in the brain of transgenic mice with overexpression of А53Т-mutant α-synuclein as an early event at synucleinopathy progression.
    Pupyshev AB; Korolenko TA; Akopyan AA; Amstislavskaya TG; Tikhonova MA
    Neurosci Lett; 2018 Apr; 672():140-144. PubMed ID: 29203207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The new line of genetically modified mice with constitutive knockout of the gene alpha synuclein to study pathogenetic aspects of differential loss of dopaminergic neurons .
    Tarasova TV; Ustyugov AA; Ninkina NN; Skvortsova VI
    Patol Fiziol Eksp Ter; 2016; 60(3):4-9. PubMed ID: 29243900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucocerebrosidase deficiency in dopaminergic neurons induces microglial activation without neurodegeneration.
    Soria FN; Engeln M; Martinez-Vicente M; Glangetas C; López-González MJ; Dovero S; Dehay B; Normand E; Vila M; Favereaux A; Georges F; Lo Bianco C; Bezard E; Fernagut PO
    Hum Mol Genet; 2017 Jul; 26(14):2603-2615. PubMed ID: 28520872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.